Novel, non-nitrocatechol catechol-O-methyltransferase inhibitors modulate dopamine neurotransmission in the frontal cortex and improve cognitive flexibility

RATIONALE: Cognitive impairment is a primary feature of many neuropsychiatric disorders and there is a need for new therapeutic options. Catechol-O-methyltransferase (COMT) inhibitors modulate cortical dopaminergic function and have been proposed as potential cognitive enhancers. Unfortunately, curr...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Psychopharmacology (Berl)
Päätekijät: Byers, Spencer, Buchler, Ingrid P., DePasquale, Michael, Rowley, Helen L., Kulkarni, Rajiv S., Pinder, Lucy, Kolobova, Anna, Li, Cailian, Au, Vinh, Akuma, Daniel, Zhang, Gongliang, Wei, Huijun, Cheetham, Sharon C., Barrow, James C., Carr, Gregory V.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7790123/
https://ncbi.nlm.nih.gov/pubmed/32474681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00213-020-05566-0
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia